\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ examination\\ reveals\\ no\\ focal\\ neurologic\\ deficit\\.\ \(0\)\
\-\ the\\ patient\\ passed\\ away\\ four\\ months\\ after\\ the\\ last\\ follow\\ up\\ mr\\ exam\\ \\(one\\ year\\ after\\ the\\ diagnosis\\ of\\ gbm\\)\\.\\ he\\ had\\ been\\ receiving\\ a\\ combination\\ of\\ chemotherapy\\ and\\ radiotherapy\\.\ \(0\)\
\-\ a\\ large\\ \\,\\ heterogeneous\\ t2\\ hyperintense\\,\\ ring\\ enhancing\\ mass\\ lesion\\ is\\ noted\\ in\\ the\\ left\\ temporoparietooccipital\\ area\\.\\ the\\ mass\\ lesion\\ is\\ surrounded\\ by\\ vasogenic\\ edema\\ and\\ exerts\\ significant\\ mass\\ effect\\ in\\ the\\ adjacent\\ cerebral\\ parenchyma\\ and\\ left\\ occipital\\ horn\\.\ \(0\)\
\-\ the\\ \\ combination\\ of\\ findings\\ are\\ consistent\\ with\\ a\\ high\\ grade\\ glioma\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\ \(8\)\
\-\ abscess\ \(594\)\
\-\ metastasis\ \(206\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ demyelinating\\ disease\ \(15\)\
\-\ arteriovenous\\ malformation\\.\ \(2\)\
\-\ 49\\-year\\ old\\ man\\ presents\\ with\\ progressive\\ onset\\ of\\ headache\\ and\\ balance\\ disorder\\.\ \(1\)\
\-\ we\\ have\\ not\\ used\\ dsc\\ mr\\ imaging\\ in\\ the\\ last\\ two\\ follow\\ up\\ exams\\ \\ because\\ there\\ was\\ an\\ obvious\\ significant\\ increase\\ in\\ the\\ size\\ of\\ the\\ enhancing\\ lesion\\ an\\ the\\ surgical\\ margin\\ compared\\ to\\ the\\ exam\\ obtained\\ at\\ three\\ months\\ after\\ the\\ surgical\\ resection\\ and\\ the\\ initiation\\ of\\ the\\ chemoradiotherapy\\.\\ \ \(0\)\
\-\ follow\\ up\\ exam\\ obtained\\ at\\ three\\ months\\ after\\ the\\ surgical\\ resection\\ and\\ the\\ initiation\\ of\\ the\\ chemoradiotherapy\\ revealed\\ an\\ small\\ enhancing\\ lesion\\ which\\ is\\ characterized\\ by\\ a\\ high\\ rcbv\\ of\\ 4\\.0\\ \\,compared\\ to\\ the\\ normal\\ contralateral\\ white\\ matter\\,\\ and\\ an\\ interval\\ increase\\ in\\ size\\ compared\\ to\\ the\\ size\\ of\\ the\\ enhancing\\ lesion\\ in\\ the\\ previous\\ exam\\.\\ \ \(0\)\
\-\ this\\ enhancing\\ lesion\\ represented\\ \\ predominantly\\ tumor\\ progression\\.\\ small\\ foci\\ of\\ reactive\\ radiation\\-induced\\ changes\\ cannot\\ be\\ excluded\\.\ \(0\)\
\-\ if\\ this\\ enhancing\\ lesion\\ represented\\ pseudoprogression\\ \\,\\ this\\ increased\\ enhancement\\ \\ would\\ have\\ been\\ stable\\ or\\ decreased\\ on\\ follow\\-up\\ studies\\.\\ conversely\\,\\ \\ the\\ enhancing\\ nodule\\ was\\ increasing\\ in\\ size\\ on\\ follow\\ up\\ exams\\.\ \(0\)\
\-\ importantly\\,\\ we\\ should\\ keep\\ in\\ mind\\ that\\ the\\ patient\\ was\\ clinically\\ getting\\ worse\\ and\\ worse\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ the\\:\\ 0\\.30650875681443107\ \(0\)\
\-\ enhancing\\:\\ 0\\.28066458789050774\ \(0\)\
\-\ lesion\\:\\ 0\\.21479595280680297\ \(0\)\
\-\ chemoradiotherapy\\:\\ 0\\.1891593848061914\ \(0\)\
\-\ size\\:\\ 0\\.1733494763671377\ \(0\)\
\-\ follow\\:\\ 0\\.17251966419454712\ \(0\)\
\-\ represented\\:\\ 0\\.16859735698161324\ \(0\)\
\-\ initiation\\:\\ 0\\.16645854830339643\ \(0\)\
\-\ up\\:\\ 0\\.1583028396808221\ \(0\)\
\-\ compared\\:\\ 0\\.15523198168514138\ \(0\)\
\-\ exams\\:\\ 0\\.12993760251094202\ \(0\)\
\-\ exam\\:\\ 0\\.12887940022846273\ \(0\)\
\-\ in\\:\\ 0\\.12737775230229284\ \(0\)\
\-\ of\\:\\ 0\\.12525378981849322\ \(0\)\
\-\ after\\:\\ 0\\.12419834652355716\ \(0\)\
\-\ we\\:\\ 0\\.12308468371916996\ \(0\)\
\-\ combination\\:\\ 0\\.1187973074992763\ \(0\)\
\-\ months\\:\\ 0\\.11176722775939135\ \(0\)\
\-\ worse\\:\\ 0\\.10723676600814704\ \(0\)\
\-\ and\\:\\ 0\\.10580581538272511\ \(0\)\
\-\ last\\:\\ 0\\.10411311194956974\ \(0\)\
\-\ increase\\:\\ 0\\.10276012378434352\ \(0\)\
\-\ temporoparietooccipital\\:\\ 0\\.10235697919505628\ \(0\)\
\-\ pseudoprogression\\:\\ 0\\.10235697919505628\ \(0\)\
\-\ an\\:\\ 0\\.09790028022741243\ \(0\)\
\-\ dsc\\:\\ 0\\.09780755806440541\ \(0\)\
\-\ surgical\\:\\ 0\\.09332468760634055\ \(0\)\
\-\ rcbv\\:\\ 0\\.0920759652827672\ \(0\)\
\-\ obtained\\:\\ 0\\.09054572142529979\ \(0\)\
\-\ conversely\\:\\ 0\\.08830066163135275\ \(0\)\
\-\ exerts\\:\\ 0\\.08680240561113513\ \(0\)\
\-\ three\\:\\ 0\\.08592951879708244\ \(0\)\
\-\ importantly\\:\\ 0\\.08322927415169822\ \(0\)\
\-\ mr\\:\\ 0\\.08282753653505034\ \(0\)\
\-\ resection\\:\\ 0\\.08205531389054477\ \(0\)\
\-\ keep\\:\\ 0\\.07902511881917455\ \(0\)\
\-\ mind\\:\\ 0\\.07902511881917455\ \(0\)\
\-\ been\\:\\ 0\\.07457938388183188\ \(0\)\
\-\ significant\\:\\ 0\\.0739094682779991\ \(0\)\
\-\ mass\\:\\ 0\\.07334392358370326\ \(0\)\
\-\ high\\:\\ 0\\.07275182161022446\ \(0\)\
\-\ getting\\:\\ 0\\.07274608804743159\ \(0\)\
\-\ demyelinating\\:\\ 0\\.07024236092710308\ \(0\)\
\-\ balance\\:\\ 0\\.06961885313317626\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.06931962865154555\ \(0\)\
\-\ passed\\:\\ 0\\.06874410490688547\ \(0\)\
\-\ gbm\\:\\ 0\\.06767470056777707\ \(0\)\
\-\ was\\:\\ 0\\.06691850762459596\ \(0\)\
\-\ multiforme\\:\\ 0\\.0666984108965631\ \(0\)\
\-\ away\\:\\ 0\\.06646705727568862\ \(0\)\
\-\ receiving\\:\\ 0\\.06646705727568862\ \(0\)\
\-\ small\\:\\ 0\\.06603125652664632\ \(0\)\
\-\ this\\:\\ 0\\.0659791997094263\ \(0\)\
\-\ surrounded\\:\\ 0\\.06580031145875068\ \(0\)\
\-\ contralateral\\:\\ 0\\.0640092208250016\ \(0\)\
\-\ have\\:\\ 0\\.0639474232043417\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.06382677366550463\ \(0\)\
\-\ horn\\:\\ 0\\.06312527943712617\ \(0\)\
\-\ vasogenic\\:\\ 0\\.0629565506472148\ \(0\)\
\-\ excluded\\:\\ 0\\.0629565506472148\ \(0\)\
\-\ arteriovenous\\:\\ 0\\.06139566979603409\ \(0\)\
\-\ deficit\\:\\ 0\\.06055375601937456\ \(0\)\
\-\ cns\\:\\ 0\\.05977062990610434\ \(0\)\
\-\ obvious\\:\\ 0\\.059521280687007704\ \(0\)\
\-\ characterized\\:\\ 0\\.05880485101138393\ \(0\)\
\-\ progression\\:\\ 0\\.058689770483728046\ \(0\)\
\-\ interval\\:\\ 0\\.05791565300449162\ \(0\)\
\-\ margin\\:\\ 0\\.05614033962164727\ \(0\)\
\-\ predominantly\\:\\ 0\\.056049486873544045\ \(0\)\
\-\ reactive\\:\\ 0\\.05493083481929554\ \(0\)\
\-\ occipital\\:\\ 0\\.054768219609378666\ \(0\)\
\-\ glioma\\:\\ 0\\.05437170297395165\ \(0\)\
\-\ by\\:\\ 0\\.05435996585984565\ \(0\)\
\-\ disorder\\:\\ 0\\.05414034935307717\ \(0\)\
\-\ ring\\:\\ 0\\.053913669863945496\ \(0\)\
\-\ clinically\\:\\ 0\\.05318953132296431\ \(0\)\
\-\ is\\:\\ 0\\.052584124391874744\ \(0\)\
\-\ foci\\:\\ 0\\.052313030069080495\ \(0\)\
\-\ parenchyma\\:\\ 0\\.05199334311414377\ \(0\)\
\-\ four\\:\\ 0\\.05186797585362313\ \(0\)\
\-\ neurologic\\:\\ 0\\.051143837312641945\ \(0\)\
\-\ hyperintense\\:\\ 0\\.05091248369176747\ \(0\)\
\-\ stable\\:\\ 0\\.050629842724603344\ \(0\)\
\-\ nodule\\:\\ 0\\.05051875020235159\ \(0\)\
\-\ increasing\\:\\ 0\\.05040874684000907\ \(0\)\
\-\ malformation\\:\\ 0\\.049364248733294626\ \(0\)\
\-\ progressive\\:\\ 0\\.04902049418213397\ \(0\)\
\-\ matter\\:\\ 0\\.04873400407150625\ \(0\)\
\-\ reveals\\:\\ 0\\.048686958916268466\ \(0\)\
\-\ previous\\:\\ 0\\.0483630528296867\ \(0\)\
\-\ at\\:\\ 0\\.048350548936504534\ \(0\)\
\-\ to\\:\\ 0\\.04800292742271695\ \(0\)\
\-\ used\\:\\ 0\\.047915971651332254\ \(0\)\
\-\ studies\\:\\ 0\\.046950644612242284\ \(0\)\
\-\ metastasis\\:\\ 0\\.04691050055122135\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.046324963193146655\ \(0\)\
\-\ grade\\:\\ 0\\.04602473784151963\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.04544736272269705\ \(0\)\
\-\ would\\:\\ 0\\.04530754467562022\ \(0\)\
\-\ effect\\:\\ 0\\.04489824994296513\ \(0\)\
\-\ because\\:\\ 0\\.044732020930960126\ \(0\)\
\-\ cerebral\\:\\ 0\\.04434284019189533\ \(0\)\
\-\ headache\\:\\ 0\\.04412189979969063\ \(0\)\
\-\ left\\:\\ 0\\.04366659773176226\ \(0\)\
\-\ white\\:\\ 0\\.04222829381063161\ \(0\)\
\-\ revealed\\:\\ 0\\.04196734593115457\ \(0\)\
\-\ should\\:\\ 0\\.041762870967883926\ \(0\)\
\-\ patient\\:\\ 0\\.041634840437704004\ \(0\)\
\-\ adjacent\\:\\ 0\\.04148766701820962\ \(0\)\
\-\ area\\:\\ 0\\.041462979982758046\ \(0\)\
\-\ abscess\\:\\ 0\\.04109904797988267\ \(0\)\
\-\ onset\\:\\ 0\\.04109904797988267\ \(0\)\
\-\ examination\\:\\ 0\\.040956717279545675\ \(0\)\
\-\ decreased\\:\\ 0\\.03964564313099129\ \(0\)\
\-\ year\\:\\ 0\\.039449795657823424\ \(0\)\
\-\ primary\\:\\ 0\\.03935580497977868\ \(0\)\
\-\ changes\\:\\ 0\\.03868159405502302\ \(0\)\
\-\ on\\:\\ 0\\.038660858536096146\ \(0\)\
\-\ focal\\:\\ 0\\.038284542829077936\ \(0\)\
\-\ edema\\:\\ 0\\.03817363332879135\ \(0\)\
\-\ lymphoma\\:\\ 0\\.038118587005368625\ \(0\)\
\-\ two\\:\\ 0\\.03800929796190564\ \(0\)\
\-\ he\\:\\ 0\\.0379010631700182\ \(0\)\
\-\ if\\:\\ 0\\.03718815049599278\ \(0\)\
\-\ enhancement\\:\\ 0\\.03683982198375173\ \(0\)\
\-\ t2\\:\\ 0\\.036823501612748735\ \(0\)\
\-\ one\\:\\ 0\\.036645527032066305\ \(0\)\
\-\ physical\\:\\ 0\\.034704658283017456\ \(0\)\
\-\ consistent\\:\\ 0\\.034704658283017456\ \(0\)\
\-\ increased\\:\\ 0\\.03461053937092111\ \(0\)\
\-\ noted\\:\\ 0\\.0339350424098941\ \(0\)\
\-\ man\\:\\ 0\\.033884727289316886\ \(0\)\
\-\ imaging\\:\\ 0\\.0336364814755646\ \(0\)\
\-\ tumor\\:\\ 0\\.03347801790729448\ \(0\)\
\-\ diagnosis\\:\\ 0\\.0331794304875851\ \(0\)\
\-\ large\\:\\ 0\\.0320693846382827\ \(0\)\
\-\ had\\:\\ 0\\.03188934839957174\ \(0\)\
\-\ findings\\:\\ 0\\.031588741653752146\ \(0\)\
\-\ presents\\:\\ 0\\.03078942312199389\ \(0\)\
\-\ which\\:\\ 0\\.029103440279335653\ \(0\)\
\-\ that\\:\\ 0\\.027775511993757246\ \(0\)\
\-\ disease\\:\\ 0\\.026866775917571077\ \(0\)\
\-\ normal\\:\\ 0\\.026132569854078365\ \(0\)\
\-\ be\\:\\ 0\\.025964028808410318\ \(0\)\
\-\ there\\:\\ 0\\.025467154561696074\ \(0\)\
\-\ not\\:\\ 0\\.02526741703333478\ \(0\)\
\-\ with\\:\\ 0\\.02506572578561269\ \(0\)\
\-\ are\\:\\ 0\\.024286761221685806\ \(0\)\
\-\ or\\:\\ 0\\.022265993204351558\ \(0\)\
\-\ no\\:\\ 0\\.02081350458346544\ \(0\)\
\-\ old\\:\\ 0\\.01894272985858488\ \(0\)\
\-\ can\\:\\ 0\\.0\ \(0\)\
